A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Avelumab (Primary) ; NHS IL12 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms COMBO
- Sponsors EMD Serono
- 26 Sep 2017 Planned number of patients changed from 140 to 170.
- 26 Sep 2017 Planned End Date changed from 30 Apr 2018 to 30 Apr 2019.
- 26 Sep 2017 Planned primary completion date changed from 30 Apr 2018 to 30 Apr 2019.